Solventum Corporation
Financials
Valuation Metrics
Solventum Corporation's Market Cap is $15.25B. At end of 2025 it was $13.80B. Ranked #721 of 3,112 in US market (top 23%), #498 of 1,667 on NYSE (top 30%), #45 of 206 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $15.25B | US#721/3,112 Sec#45/206 |
| Revenue | $8.26B | US#658/3,112 Sec#37/206 |
| Net Income | $1.43B | US#415/3,112 Sec#20/206 |
| Total Assets | $14.10B | US#789/3,112 Sec#36/206 |
| Net Assets | $4.97B | US#706/3,112 Sec#40/206 |
| Employees | 20,584 | US#356/3,112 Sec#31/206 |
| Value | ||
| P/E | 10.65x | US#287/3,112 Sec#5/206 |
| P/B | 3.07x | US#1,700/3,112 Sec#102/206 |
| P/S | 1.85x | US#1,177/3,112 Sec#84/206 |
| EV/EBITDA | 7.18x | US#362/3,112 Sec#11/206 |
| FCF Yield | -1.33% | US—/3,112 Sec—/206 |
| Profitability | ||
| ROE | 28.82% | US#322/3,112 Sec#14/206 |
| ROA | 10.16% | US#440/3,112 Sec#26/206 |
| Op. Margin | 25.54% | US#629/3,112 Sec#18/206 |
| Revenue Growth | -3.04% | US#2,423/3,112 Sec#179/206 |
| Earnings Growth | -90.51% | US#2,030/3,112 Sec#104/206 |
| Financial Health | ||
| Debt Ratio | 183.70% | US#1,700/3,112 Sec#148/206 |
| Total Debt | $5.08B | US#655/3,112 Sec#34/206 |
| FCF | $-203M | US#2,732/3,112 Sec#202/206 |
| Cash | $561M | US#999/3,112 Sec#54/206 |
| Current Ratio | 1.07x | US#2,178/3,112 Sec#188/206 |
| Net Debt/EBITDA | 1.64x | US#1,252/3,112 Sec#70/206 |
| Performance | ||
| 1Y Return | 22.74% | US#1,460/3,112 Sec#100/206 |
| 1M Return | 12.48% | US#394/3,112 Sec#36/206 |
| From 52W High | -0.69% | US#74/3,112 Sec#2/206 |
| 1Y MDD | -27.46% | US#1,187/3,112 Sec#38/206 |
| Trading | ||
| Volume | 1,063,794 shares | US#1,414/3,112 Sec#96/206 |
| Trading Value | $93M | US#957/3,112 Sec#75/206 |
| Per Share | ||
| EPS | $8.94 | US#297/3,112 Sec#20/206 |
| BPS | $29.00 | US#888/3,112 Sec#53/206 |
Company Info
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.